Biomolecules & biomedicine最新文献

{"title":"Competing cardiovascular and tumor-specific mortality in malignant phyllodes tumor.","authors":"İsmail Zihni, Burcu Zihni, Mehmet Zafer Sabuncuoğlu","doi":"10.17305/bb.2026.14688","DOIUrl":"https://doi.org/10.17305/bb.2026.14688","url":null,"abstract":"<p><p>Malignant phyllodes tumor of the breast is a rare neoplasm, and its long-term competing causes of death remain insufficiently characterized. This study aimed to quantify phyllodes-specific and cardiovascular mortality and determine whether cardiovascular mortality exceeds that expected in the general female population. Women with histologically confirmed malignant phyllodes tumor diagnosed between 2000 and 2020 were identified in the Surveillance, Epidemiology, and End Results (SEER) 17-registry database. Phyllodes-specific, cardiovascular, and other-cause mortality were evaluated using competing-risk methods, while cardiovascular standardized mortality ratios (SMRs) were calculated using United States female circulatory-disease rates and person-time distributed across attained-age strata by Lexis expansion. Among 2106 women followed for a median of 165 months, 294 died from phyllodes-specific causes, 83 from cardiovascular causes, and 163 from other causes. Phyllodes-specific mortality remained the dominant competing risk throughout follow-up, with 180-month cumulative incidences of 14.6% for phyllodes-specific death and 4.4% for cardiovascular death. Cardiovascular mortality was not elevated relative to the general female population when person-time was standardized by attained age (SMR 0.92; 95% confidence interval 0.74-1.14) or additionally by calendar period (SMR 1.00; 95% confidence interval 0.80-1.24). In contrast, assigning all person-time to age at diagnosis produced an inflated SMR of 1.95. Phyllodes-specific death therefore remains the principal long-term mortality risk in malignant phyllodes tumor, whereas the apparent excess cardiovascular mortality results from incorrect person-time allocation rather than a true increase in risk.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148681383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare <i>VDR </i>variant rs1338135647 and lower vitamin D levels in autism spectrum disorder: An exploratory case-control study in Indonesian children.","authors":"Sunny Mariana Samosir, Citrawati Dyah Kencono Wungu, Riza Noviandi, Zilfalil Bin Alwi, Wan Rohani Wan Taib, Yunias Setiawati, Prastiya Indra Gunawan","doi":"10.17305/bb.2026.14353","DOIUrl":"https://doi.org/10.17305/bb.2026.14353","url":null,"abstract":"<p><p>Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition arising from interactions between genetic susceptibility and environmental factors, including vitamin D status. This study investigated the associations of serum vitamin D levels and vitamin D receptor (VDR) gene variants with ASD in Indonesian children. This exploratory case-control study included 80 children aged 24-59 months from Surabaya, Indonesia, comprising 40 children with ASD and 40 typically developing controls. Serum 25-hydroxyvitamin D3 (25[OH]D3) concentrations were measured using an enzyme-linked immunosorbent assay, while the VDR region containing rs731236 was amplified by polymerase chain reaction and analyzed using bidirectional Sanger sequencing. Sequencing additionally identified rs11574113, rs7975232, and the rare missense variant rs1338135647 (p.Gly375Asp). Children with ASD had lower serum 25(OH)D3 concentrations than controls (median, 46.13 vs 69.27 ng/mL; p = 0.027), and the difference remained significant after adjustment for age and sex (adjusted median difference, -24.86 ng/mL; 95% confidence interval [CI], -42.42 to -7.30; p = 0.007). The rs1338135647 AG genotype was more frequent in children with ASD than in controls (22.5% vs 2.5%) and remained associated with ASD after adjustment for age and sex using Firth penalized logistic regression (odds ratio, 6.44; 95% CI, 1.21-67.64; p = 0.028). No significant associations were observed for the other VDR variants. Lower vitamin D levels and the rare rs1338135647 variant may independently co-occur with ASD in Indonesian children; however, these hypothesis-generating findings require replication and functional validation in larger independent cohorts.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148633056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline visceral fat area and early visceral fat loss predict survival in HER2-negative advanced gastroesophageal adenocarcinoma treated with immunochemotherapy.","authors":"Shubin Liang, Xijian Zhang, Shengnan Wang, Baokai Wang, Hanzheng Wang, Muhammad Ali, Shi Jin","doi":"10.17305/bb.2026.14498","DOIUrl":"https://doi.org/10.17305/bb.2026.14498","url":null,"abstract":"<p><p>Immune checkpoint inhibitor (ICI)-based chemotherapy has improved outcomes in human epidermal growth factor receptor 2 (HER2)-negative advanced gastroesophageal adenocarcinoma (GEA), but clinically accessible prognostic biomarkers remain limited. This study evaluated the prognostic significance of baseline and early changes in computed tomography (CT)-derived body composition and peripheral inflammatory markers in patients receiving first-line immunochemotherapy. This retrospective single-center study included 188 patients with unresectable HER2-negative advanced GEA who completed at least three treatment cycles and underwent baseline and post-cycle 3 CT and laboratory assessments. Visceral fat area (VFA), subcutaneous fat area, and skeletal muscle area were measured at the third lumbar vertebral level, and inflammatory and nutritional indices, including the neutrophil-to-lymphocyte ratio (NLR), were calculated. Associations with progression-free survival (PFS), overall survival (OS), and treatment response were assessed using Cox regression and exploratory threshold-based analyses. During a median follow-up of 16.2 months, 102 PFS events and 75 deaths occurred. In multivariable baseline analyses, a higher Charlson Comorbidity Index, elevated carcinoembryonic antigen (CEA), higher NLR, and lower VFA were independently associated with shorter PFS, whereas elevated CEA and lower VFA were independently associated with shorter OS. Each 1000-mm² increase in VFA was associated with lower risks of progression or death (hazard ratio [HR], 0.912; 95% confidence interval [CI], 0.863-0.964) and death (HR, 0.919; 95% CI, 0.864-0.977). Patients with high baseline VFA also had a higher objective response rate than those with low VFA (45.8% vs. 28.4%). In exploratory threshold-based longitudinal analyses, a VFA reduction greater than 20% was associated with shorter PFS and OS; however, continuous analyses of body composition changes did not confirm independent associations. Higher baseline VFA may represent a favorable host-related prognostic marker in HER2-negative advanced GEA treated with immunochemotherapy, whereas the prognostic value of early VFA loss requires prospective external validation.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary polyphenols in colorectal cancer - Mechanisms, clinical evidence, and bioavailability of curcumin, resveratrol, and epigallocatechin-3-gallate: A review.","authors":"Haifa A Alqahtani","doi":"10.17305/bb.2026.14667","DOIUrl":"https://doi.org/10.17305/bb.2026.14667","url":null,"abstract":"<p><p>Dietary polyphenols have attracted considerable interest as potential preventive and therapeutic agents in colorectal cancer (CRC), although their clinical value remains uncertain. This narrative review aimed to critically evaluate the mechanistic, epidemiological, and clinical evidence for curcumin, resveratrol, and epigallocatechin-3-gallate (EGCG), with particular emphasis on the gap between preclinical activity and human efficacy. PubMed/MEDLINE, Scopus, and Web of Science were searched for English-language studies published from January 2000 to January 2026, including in vitro and animal investigations, epidemiological studies, and clinical trials. Preclinical evidence consistently showed that these polyphenols inhibit nuclear factor kappa B (NF-κB), phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR), signal transducer and activator of transcription 3 (STAT3), and Wnt/β-catenin signaling, while promoting apoptosis, antioxidant responses, and suppression of inflammation, proliferation, angiogenesis, and metastasis. These effects were associated with reduced tumor burden in animal models. Epidemiological studies suggested modest protective associations, particularly for green tea consumption, but findings were inconsistent, frequently confounded, and of limited generalizability. Human trials predominantly demonstrated biomarker modulation, whereas effects on adenoma recurrence were mixed and no consistent benefits were observed for tumor regression, recurrence, progression-free survival, or overall survival. Clinical translation is further limited by poor absorption, rapid metabolism, uncertain activity of metabolites, formulation variability, and potential hepatotoxicity and drug interactions, although high local colorectal exposure may remain biologically relevant. Curcumin, resveratrol, and EGCG therefore show strong mechanistic potential but cannot currently be recommended as stand-alone CRC therapies. They should be regarded as investigational preventive or adjunctive agents pending adequately powered randomized trials using standardized formulations, optimized dosing, and clinically meaningful endpoints.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive immunohistochemistry in non-small cell lung cancer - Biomarkers, companion diagnostics, and molecular testing: A narrative review.","authors":"Semir Vranić, Inga Rose, Nataliya Kuzmova, Zoran Gatalica","doi":"10.17305/bb.2026.14794","DOIUrl":"https://doi.org/10.17305/bb.2026.14794","url":null,"abstract":"<p><p>Immunohistochemistry (IHC) is central to precision oncology in advanced non-small cell lung cancer (NSCLC), although its predictive value and the need for molecular confirmation differ across biomarkers. This narrative review aimed to summarize the clinical utility, validated assays, scoring systems, diagnostic performance, and testing algorithms for predictive IHC biomarkers in NSCLC. Recent guidelines, regulatory documents, and selected analytical and clinical studies were reviewed for programmed death-ligand 1 (PD-L1), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 receptor tyrosine kinase (ROS1), mesenchymal-epithelial transition factor receptor (c-Met), B-Raf proto-oncogene serine/threonine kinase V600E (BRAF V600E), pan-tropomyosin receptor kinase (pan-TRK), human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor (EGFR). PD-L1 and ALK are established IHC-based predictive assays, although PD-L1 interpretation remains assay-, platform-, and cutoff-specific. VENTANA ALK D5F3 and VENTANA MET SP44 RxDx are clinically validated companion diagnostics, whereas HER2 IHC score 3+ may support eligibility for trastuzumab deruxtecan in the tumor-agnostic setting. ROS1, BRAF V600E, pan-TRK, and non-companion-diagnostic c-Met or HER2 assays are best used for screening or triage and generally require molecular confirmation. EGFR mutation-specific IHC is not recommended because of insufficient diagnostic performance. Overall, IHC enables rapid, tissue-sparing biomarker assessment but should be integrated with broad genomic and transcriptomic next-generation sequencing (NGS), particularly when alteration-specific findings are negative, equivocal, or discordant.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148610941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of the C-reactive protein-to-albumin ratio in acute pancreatitis.","authors":"Ali Avci, Zeynep Gok Sargin, Fatih Sargin, Esved Melih Acikgoz, Celal Dogan, Ahmet Caliskan, Yavuz Fatih Yavuz","doi":"10.17305/bb.2026.14587","DOIUrl":"https://doi.org/10.17305/bb.2026.14587","url":null,"abstract":"<p><p>Acute pancreatitis (AP) has a highly variable clinical course, making early identification of patients at risk of severe acute pancreatitis (SAP) essential for timely management. This study evaluated the ability of the C-reactive protein-to-albumin ratio (CRP/albumin ratio) at hospital admission to predict SAP and compared its performance with established prognostic scoring systems. This retrospective, single-center cohort study included 502 adults admitted with AP between January 2024 and December 2025. Disease severity was classified according to the revised Atlanta classification. The CRP/albumin ratio was calculated at admission and during serial follow-up, and its predictive performance was assessed using receiver operating characteristic (ROC) curve analysis and Firth logistic regression. Overall, 308 patients (61.4%) had mild, 130 (25.9%) had moderately severe, and 64 (12.7%) had severe AP. The admission CRP/albumin ratio was significantly higher in patients with SAP than in those with less severe disease (p<0.001), and the difference persisted during follow-up. The ratio demonstrated acceptable discrimination for SAP, with an area under the curve (AUC) of 0.796 (95% confidence interval [CI]: 0.666-0.925). A cut-off value of 24.89 provided 69.6% sensitivity and 86.0% specificity. Its discriminatory performance was comparable to that of the Acute Physiology and Chronic Health Evaluation II (APACHE II) score (AUC: 0.800; p=0.959). In complete-case multivariable Firth logistic regression involving 66 patients, including 23 with SAP, the CRP/albumin ratio remained independently associated with SAP (odds ratio: 1.035; 95% CI: 1.011-1.072; p<0.001). The admission CRP/albumin ratio may therefore serve as a simple and readily available complementary marker for early risk stratification in AP, although the proposed cut-off requires validation in prospective multicenter studies.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148581417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conditional survival nomogram for dynamic prognostic prediction in older women with surgically treated breast cancer.","authors":"Haolong Niu, Jinying Zhang","doi":"10.17305/bb.2026.14576","DOIUrl":"https://doi.org/10.17305/bb.2026.14576","url":null,"abstract":"<p><p>Prognostic estimates established at breast cancer diagnosis may become less informative as patients survive longer, particularly among older women with substantial competing mortality risks. This study aimed to develop and internally validate a dynamic conditional survival (CS) nomogram for predicting breast cancer-specific survival (BCSS) in surgically treated women aged ≥70 years. Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) database for patients diagnosed between 2010 and 2015. The 44,354 eligible patients were randomly assigned to training (n = 31,047) and internal validation (n = 13,307) cohorts. A random survival forest (RSF) algorithm was used to select prognostic variables, which were incorporated into a multivariable Cox regression model to construct a nomogram combining conventional and conditional BCSS estimates. Model performance was evaluated using the concordance index (C-index), time-dependent receiver operating characteristic curves, calibration analysis, and decision curve analysis. The RSF algorithm selected age, T stage, N stage, M stage, histological grade, and molecular subtype as independent predictors of BCSS. The estimated probability of surviving to 10 years increased from 88% at diagnosis to 89%, 92%, 95%, and 97% after surviving 1, 3, 5, and 7 years, respectively. The model achieved C-indices of 0.833 and 0.830 in the training and validation cohorts, respectively, with time-dependent areas under the curve ranging from 0.841 to 0.882. Calibration was satisfactory, and the nomogram provided greater net benefit than tumor-node-metastasis staging alone. This internally validated nomogram provides individualized, time-updated BCSS estimates and may support dynamic risk stratification during long-term follow-up, although external validation is required before clinical implementation.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148581420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Silymarin in type 2 diabetes - Targeting adipose tissue dysfunction and pancreatic β-cell damage: A review.","authors":"Nasr-Eddine Kebir, Naima Berber, Yamina Mehdi","doi":"10.17305/bb.2026.14416","DOIUrl":"https://doi.org/10.17305/bb.2026.14416","url":null,"abstract":"<p><p>Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and progressive pancreatic β-cell dysfunction, processes strongly influenced by adipose tissue inflammation, oxidative stress, and dysregulated lipid metabolism. Silymarin, a flavonolignan complex derived from Silybum marianum, has attracted interest as a potential adjunctive agent because of its antioxidant, anti-inflammatory, and metabolic regulatory properties. This review summarizes experimental and clinical evidence on the effects of silymarin and its major bioactive constituent, silibinin, on adipose tissue dysfunction and pancreatic β-cell injury in T2DM. Available evidence was narratively synthesized with emphasis on adipogenesis, lipid accumulation, inflammatory signaling, insulin signaling, oxidative stress, and β-cell survival. Experimental studies indicate that silymarin may reduce adipogenesis and lipid accumulation through modulation of adipogenic transcription factors, including peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancer-binding protein alpha (C/EBPα), and activation of AMP-activated protein kinase (AMPK). Silymarin may also attenuate pro-inflammatory cytokine production, enhance antioxidant defenses, and protect pancreatic β-cells from glucotoxicity-, lipotoxicity-, and cytokine-induced apoptosis. Limited clinical data suggest potential improvements in glycemic control, insulin resistance, lipid parameters, and systemic inflammation. Overall, silymarin shows promise as an adjunctive strategy for metabolic dysfunction in T2DM; however, standardized formulations and well-designed randomized clinical trials are needed to confirm its efficacy, safety, and clinical relevance.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.","authors":"Tiantian Tang, Jingxuan Wang, Tao Sun, Lina Zhang, Fanfan Li, Bing Zhao, Guohui Han, Zhongsheng Tong, Hua Yang, Yongmei Yin, Xiangshun Kong, Ying Wang, Jianyun Nie, Lixia Ma, Yongqiang Zhang, Jing Luo, Changping Shan, Jing Yao, Shisheng Tan, Xiaoling Ling, Hongmei Sun, Huihui Li, Li Ma, Tao Zhou, Yunjiang Liu, Yixin Qi, Zhenchuan Song, Yuntao Li, Chao Yang, Tianli Hui, Meiqi Wang, Haoqi Wang, Xi Zhang, Wenhui Zhao, Yanhui Li, Mengmeng Li, Ying Xin, Xuan Luo, Deliang Yin, Hongmei Luo, Huan Liu, Qianyun Lu, Jing Yuan, Cuizhi Geng, Qingyuan Zhang","doi":"10.17305/bb.2026.14334","DOIUrl":"https://doi.org/10.17305/bb.2026.14334","url":null,"abstract":"<p><p>SYHX2011 is a novel albumin-bound paclitaxel formulation designed to simplify drug preparation and reduce skin rash by replacing most non-particulate human serum albumin with mannitol and sucrose. This exploratory analysis evaluated updated survival outcomes after extended follow-up of a multicenter, randomized, double-blind, phase III trial comparing SYHX2011 with approved albumin-bound paclitaxel (PAB; Keaili®) in patients with unresectable locally advanced or metastatic breast cancer. Overall, 459 patients were randomized 1:1 to receive SYHX2011 or PAB. At the December 29, 2025 data cutoff, median follow-up was 25.2 and 25.0 months, respectively. Median progression-free survival (PFS) was 7.6 months with SYHX2011 and 5.6 months with PAB (p=0.028; hazard ratio [HR]=0.79, 95% confidence interval [CI]: 0.63-1.01). Median overall survival (OS) was not reached with SYHX2011 and was 24.3 months with PAB (p=0.11; HR=0.84, 95% CI: 0.64-1.11). Descriptive trends toward longer PFS and OS with SYHX2011 were observed across hormone receptor-positive, triple-negative, first-line, and later-line subgroups. Although OS data remain immature and subgroup findings require cautious interpretation, the updated results support continued clinical evaluation of SYHX2011 as an albumin-bound paclitaxel option for advanced breast cancer.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular versus breast cancer mortality in men with breast cancer: An age-stratified SEER competing-risk study.","authors":"İsmail Zihni, Burcu Zihni, Mehmet Zafer Sabuncuoğlu","doi":"10.17305/bb.2026.14604","DOIUrl":"https://doi.org/10.17305/bb.2026.14604","url":null,"abstract":"<p><p>Male breast cancer is rare and predominantly affects older patients, who face a substantial competing burden of cardiovascular disease. We aimed to characterize age-specific cumulative incidences of breast cancer, cardiovascular, and other-cause mortality and determine when cardiovascular cumulative incidence overtakes that of breast cancer. Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified men diagnosed with non-metastatic invasive breast cancer during 2000-2022. Cause-specific cumulative incidence was estimated using the Aalen-Johansen estimator, with cardiovascular-breast cancer differences at 5 and 10 years as the primary comparison. Factors associated with cardiovascular death were evaluated using cause-specific Cox and complementary Fine-Gray models. Among 6702 men followed for a median of 67 months, 665 cardiovascular deaths occurred. Mortality patterns were strongly age-dependent. In men aged 80 years or older, cardiovascular cumulative incidence exceeded breast cancer cumulative incidence by 4.6 percentage points at 5 years and 14.6 percentage points at 10 years. In men aged 70-79 years, the differences were not significant at either time point, although an exploratory sustained crossover occurred near 13.6 years. After adjustment, age 80 years or older was strongly associated with cardiovascular death compared with age 60-69 years (hazard ratio 8.54, 95% confidence interval 6.89-10.60); regional stage and unmarried status were also associated with higher cardiovascular mortality. In men with non-metastatic breast cancer, cardiovascular cumulative incidence overtakes that of breast cancer early after diagnosis in the oldest patients. These findings support age-aware cardiovascular attention during survivorship but do not establish that intensified cardiovascular surveillance improves outcomes.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}